2024-02-13T00:00:00.000+11:00
Ongoing

CODEBREAK-202

CODEBREAK-202
Lung cancer

A Phase 3 multicenter, randomized, open label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Patients with Stage IV and Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Positive for KRAS G12C

A Phase 3 multicenter, randomized, open label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Patients with Stage IV and Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Positive for KRAS G12C

Trial overview

Topic

Lung cancer

Trial registration
Number: NCT05920356
Study details

The primary objective of this study is to compare progression-free survival (PFS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet chemotherapy.

Further information

Please click here for more information

Location

GenesisCare North Shore – PI: Dr Nick Pavlakis

GenesisCare North Shore – PI: Dr Nick Pavlakis :::

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.